Astellas Seeks To Preserve Lipitor Deal

Japanese drugmaker Astellas is seeking a declaratory judgement to confirm that a co-marketing deal with Pfizer, regarding the latter's blockbuster cholesterol-lowering drug Lipitor (atorvastatin), will continue until 2016. The drug was Astellas' top-selling product last year, notching up sales of JPY91.5bn (US$780mn). At a time when the growth of the global statins market appears to be cooling, Lipitor's sales grew approximately 4.7% during the last Japanese financial year, despite deep price cuts in the domestic

To read the full article, please choose one of the following options: